Neogen (NEOG) assigns Avi Pelossof to audit and compensation committees

Rhea-AI Filing Summary

Neogen Corporation filed an amended report to update information about a recent board appointment. The company previously disclosed that Avi Pelossof would join its Board of Directors effective October 24, 2025. This amendment adds details on his governance roles.

Neogen states that Mr. Pelossof has been appointed to serve on its Audit Committee and its Compensation and Talent Management Committee. The change clarifies his specific committee responsibilities, which were determined after the original report filed on August 14, 2025.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000711377true00007113772025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

(Amendment No. 1)

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Neogen Corporation

(Exact name of Registrant as Specified in Its Charter)

Michigan			0-17988	38-2367843
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
620 Lesher Place
Lansing, Michigan				48912
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (517) 372-9200

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.16 par value per share		NEOG		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Form 8-K/A amends the Form 8-K filed on August 14, 2025 to include the newly appointed director's committee appointments, which were determined subsequent to the original filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Subsequent to issuing its original announcement that Avi Pelossof was appointed to its Board of Directors, effective October 24, 2025, Mr. Pelossof has been appointed to serve on the Audit and Compensation and Talent Management Committees.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEOGEN CORPORATION
Date:	October 28, 2025	By:	/s/ Amy M. Rocklin
			Name: Amy M. Rocklin Title: Chief Legal & Compliance Officer, Corporate Secretary

FAQ

What did Neogen (NEOG) change in its amended 8-K/A filing?

Neogen updated a prior disclosure to add committee assignments for new director Avi Pelossof. The amendment clarifies that he will serve on the Audit Committee and the Compensation and Talent Management Committee, information that was not finalized when the original report was filed in August 2025.

Who is the newly appointed director mentioned by Neogen (NEOG)?

The filing identifies Avi Pelossof as a newly appointed member of Neogen’s Board of Directors. It further explains that, in addition to joining the board, he has been selected to serve on the Audit Committee and the Compensation and Talent Management Committee effective October 24, 2025.

When does Avi Pelossof’s board service at Neogen (NEOG) become effective?

Neogen states that Avi Pelossof’s appointment to its Board of Directors is effective October 24, 2025. The amended report then adds that, following this effective date, the company determined he will serve on the Audit Committee and the Compensation and Talent Management Committee.

Which board committees will Avi Pelossof serve on at Neogen (NEOG)?

According to the amendment, Avi Pelossof will serve on Neogen’s Audit Committee and its Compensation and Talent Management Committee. These specific committee roles were decided after the original August 14, 2025 disclosure and prompted the company to file the updated 8-K/A report.

Why did Neogen (NEOG) file an Amendment No. 1 to its current report?

Neogen filed Amendment No. 1 to add committee assignments for new director Avi Pelossof that were not available at the time of the initial filing. The amendment specifically notes his appointments to the Audit Committee and the Compensation and Talent Management Committee, providing more complete governance information.

Who signed Neogen’s (NEOG) amended 8-K/A and in what capacity?

The amended report was signed on behalf of Neogen Corporation by Amy M. Rocklin. The filing lists her titles as Chief Legal & Compliance Officer and Corporate Secretary, indicating she is the authorized officer executing the report under the Securities Exchange Act of 1934.